Skip to main content
Caplight Logo









Endovascular Engineering, Inc.

Endovascular Engineering, Inc.

Private
Menlo Park, CaliforniaHealthcare & Life Scienceshttps://endovascularengineering.com/

Last Round

Series C

Apr 7, 2026

Est. Valuation

$70M

Total Funding Raised

$137.3M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Endovascular Engineering, Inc. is a medical technology company that develops and deploys next-generation clot removal technologies targeting venous thromboembolism.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

thrombectomy systemendovascular devicesminimally invasive surgeryvascular interventionmedical device manufacturerinterventional cardiologyvascular surgerymechanical thrombectomyaspiration cathetermedtechclinical stage medical devicevascular disease treatment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Endovascular Engineering, Inc. Comparables

Compare Endovascular Engineering, Inc. with similar companies based on industry and business-model similarity.

Endovascular Engineering, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Jupiter Endovascular
89%
Inquis Medical
84%
Imperative Care
82%

Endovascular Engineering, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CApr 7, 2026
Series BFeb 18, 2025
Series A ExtensionApr 5, 2022
GrantSep 20, 2021

Key People

Founding team and executive leadership

Mike Rosenthal

Chief Operating Officer, Co-Founder

Founding Team

Justin Farry

CFO

Executive Team

Endovascular Engineering, Inc. Investors

Notable investors and investment history

Endovascular Engineering, Inc. investors
InvestorRounds
Philips VenturesSeries B
NIH RADxGrant
415 CapitalSeries C, Series B
Gilde HealthcareSeries C
Santé VenturesSeries C, Series B, Series A Extension
Norwest Venture PartnersSeries C
Panakès PartnersSeries C, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 18, 2026

    Grew 31% QoQ, from 39 to 51 employees.

  • Apr 7, 2026

    $80M Series C round completed.

Endovascular Engineering, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Endovascular Engineering, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Endovascular Engineering, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersMenlo Park, California
Employee Range51
Year Founded2019
Last FundingApr 7, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?